Utility of High Sensitivity Troponin I to Monitor Cardiac Allograft Vasculopathy Progression

Lipoprotein (a) and lipid-lowering treatment from the perspective of a cardiac surgeon. An impact on the prognosis in patients with aortic valve replacement and after heart transplantation

“…Based on information from Refs. [ [1] , [2] , [3] , [4] , [5] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [32] , [33] , [34] , [35] , [36] , [37] , [44] , [45] , [46] , [47] , [48] , [49] , [50] ]. The elements of the figure were created using SERVIER MEDICAL ART (CC BY 4.0).…”

“…Patients with Lp(a) ≥30 mg/dl (≥75 nmol/l) also showed an earlier onset of CAV compared with those with normal Lp(a) level [ 34 ]. In over 10 years of follow-up of HTx patients, it was found that each increase in Lp(a) level by 10 mg/dl (25 nmol/l) independently increased the risk of CAV by as much as 26 % [ 37 ]. Thus, it seems reasonable to measure Lp(a) levels in HTx patients to assess the CAV risk.…”